IL-15 Protein (AA 49-162, Q149D, Q156D) (Fc Tag)

Catalog No. ABIN6253292

Recombinant IL-15 protein expressed in CHO Cells.

Quick Overview for IL-15 Protein (AA 49-162, Q149D, Q156D) (Fc Tag) (ABIN6253292)

Target: IL-15 (IL15) (Interleukin 15 (IL15))

Protein Type: Recombinant

Origin: Human

Source: CHO Cells

Purity: >98 % (SDS-PAGE)

Product Details

Protein Characteristics: AA 49-162, Q149D, Q156D

Purification tag / Conjugate: This IL-15 protein is labelled with Fc Tag.

Purpose: IL-15 (mutant) (human):Fc (human) (rec.)

Specificity: The extracellular domain of human IL-15 (aa 49-162) including mutations at Q149D and Q156D is fused to the N-terminus of the Fc region of human IgG1.

Characteristics: Protein. The extracellular domain of human IL-15 (aa 49-162) including mutations at Q149D and Q156D is fused to the N-terminus of the Fc region of human IgG1. Source: CHO cells. Endotoxin content: <0.06EU/μg protein (LAL test, Lonza). Lyophilized from 0.2μm-filtered solution in PBS. Purity: >98 % (SDS-PAGE). Interleukin-15 (IL-15) has a broad spectrum of biological activities. It is crucial for the development, proliferation, survival and differentiation of multiple cells from both innate and adaptive immune systems. IL-15 up-regulation has a central role in the development of several autoimmune or chronic inflammatory disorders. Targeting IL-15 or its receptor may have a valuable impact on the treatment of immune-mediated diseases. IL-15 participates in the development of important immune antitumor mechanisms. It activates CD8(+) T cells, natural killer (NK) cells, NK T cells, and can promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumor-associated antigens. In pre-clinical studies IL-15 has been found to demonstrate potentiated antitumor effects following pre-association with IL-15Ralpha, or when used in combination with chemotherapy, adoptive therapy, monoclonal antibodies, and tumor vaccines.

Endotoxin Level: <0.06EU/μg protein (LAL test, Lonza).

Biological Activity Comment: This mutant IL-15/Fc fusion protein specifically binds to the IL-15R, competitively inhibits IL-15-triggered cell proliferation, promotes transplant tolerance, does not activate the STAT-signaling pathway, and exerts a prolonged circulating half-life caused by the modified Fc domain.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: Lot specific

Buffer: Lyophilized from 0.2μm-filtered solution in PBS.

Handling Advice: Avoid freeze/thaw cycles.

Storage: 4 °C,-20 °C

Storage Comment:

Short Term Storage: +4°C

Long Term Storage: -20°C

Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.

Target Details

Target: IL-15 (IL15) (Interleukin 15 (IL15))

Alternative Name: IL-15

Background:

Alternate Names/Synonyms: Interleukin-15

Product Description: Interleukin-15 (IL-15) has a broad spectrum of biological activities. It is crucial for the development, proliferation, survival and differentiation of multiple cells from both innate and adaptive immune systems. IL-15 up-regulation has a central role in the development of several autoimmune or chronic inflammatory disorders. Targeting IL-15 or its receptor may have a valuable impact on the treatment of immune-mediated diseases. IL-15 participates in the development of important immune antitumor mechanisms. It activates CD8(+) T cells, natural killer (NK) cells, NK T cells, and can promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumor-associated antigens. In pre-clinical studies IL-15 has been found to demonstrate potentiated antitumor effects following pre-association with IL-15Ralpha, or when used in combination with chemotherapy, adoptive therapy, monoclonal antibodies, and tumor vaccines.

NCBI Accession: NP_751914

Pathways: JAK-STAT Signaling, Glycosaminoglycan Metabolic Process